207 related articles for article (PubMed ID: 38461486)
1. Anti-calcitonin Gene-Related Peptide Monoclonal Antibodies in Migraine: Focus on Clinical Pharmacokinetics.
Janković SM; Janković SV
Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):277-293. PubMed ID: 38461486
[TBL] [Abstract][Full Text] [Related]
2. Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Migraine: Focus on Drug Interactions.
Janković SM; Janković SV
Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):263-275. PubMed ID: 38457093
[TBL] [Abstract][Full Text] [Related]
3. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
Sacco S; Bendtsen L; Ashina M; Reuter U; Terwindt G; Mitsikostas DD; Martelletti P
J Headache Pain; 2019 Jan; 20(1):6. PubMed ID: 30651064
[TBL] [Abstract][Full Text] [Related]
4. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody.
Kielbasa W; Helton DL
Cephalalgia; 2019 Sep; 39(10):1284-1297. PubMed ID: 30917684
[TBL] [Abstract][Full Text] [Related]
5. Migraine therapeutics differentially modulate the CGRP pathway.
Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials.
Xu D; Chen D; Zhu LN; Tan G; Wang HJ; Zhang Y; Liu L
Cephalalgia; 2019 Aug; 39(9):1164-1179. PubMed ID: 30789292
[TBL] [Abstract][Full Text] [Related]
7. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
8. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
Nagaraj K; Vandenbussche N; Goadsby PJ
Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149
[TBL] [Abstract][Full Text] [Related]
9. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
Chiang CC; Schwedt TJ
Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
[TBL] [Abstract][Full Text] [Related]
10. Medications Approved for Preventing Migraine Headaches.
Spindler BL; Ryan M
Am J Med; 2020 Jun; 133(6):664-667. PubMed ID: 32145209
[TBL] [Abstract][Full Text] [Related]
11. Network meta-analysis on efficacy and safety of different anti-CGRP monoclonal antibody regimens for prophylaxis and treatment of episodic migraine.
Shi M; Guo J; Li Z; Sun H; Yang X; Yang D; Zhao H
Neurol Res; 2021 Nov; 43(11):932-949. PubMed ID: 34281473
[TBL] [Abstract][Full Text] [Related]
12. The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy.
Raffaelli B; Reuter U
Neurotherapeutics; 2018 Apr; 15(2):324-335. PubMed ID: 29616494
[TBL] [Abstract][Full Text] [Related]
13. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
Caronna E; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
Handb Clin Neurol; 2024; 199():107-124. PubMed ID: 38307640
[TBL] [Abstract][Full Text] [Related]
14. CGRP antagonists for decreasing migraine frequency: New options, long overdue.
Bucklan J; Ahmed Z
Cleve Clin J Med; 2020 Apr; 87(4):211-218. PubMed ID: 32238376
[TBL] [Abstract][Full Text] [Related]
15. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
16. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
Edvinsson L; Haanes KA; Warfvinge K; Krause DN
Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
[TBL] [Abstract][Full Text] [Related]
17. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
Tringali G; Navarra P
Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis.
Soni P; Chawla E
Clin Neurol Neurosurg; 2021 Oct; 209():106893. PubMed ID: 34464833
[TBL] [Abstract][Full Text] [Related]
20. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
